Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
L01CD02 DOCETAXEL GP PHARM G Docetaxel - 40mg/ml 80mg/2ml Injectable concentrated solution+diluent 16,777,239 L.L
L01CD02 DOCETAXEL GP PHARM G Docetaxel - 40mg/ml 20mg/0.5ml Injectable concentrated solution+diluent 4,567,721 L.L
L01CD02 DOCETAXEL ACCORD G Docetaxel - 80mg/4ml 80mg/4ml Injectable concentrate for solution 15,099,641 L.L
L01CD02 DOCETAXEL SPC G Docetaxel - 80mg/4ml 80mg/4ml Injectable concentrate for solution 16,906,027 L.L
L01CD02 DOCETAXEL EBEWE G Docetaxel - 80mg/8ml 80mg/8ml Injectable solution 19,518,281 L.L
A03FA03 DOMPERIDONE BIOGARAN G Domperidone - 10mg 10mg Tablet, coated 116,914 L.L
A03FA03 DOMIDONE CHAPHA SUGAR FREE G Domperidone - 5mg/5ml 5mg/5ml Suspension 319,963 L.L
N06DA02 DONEPEZIL/ GENEPHARM G Donepezil - 10mg 10mg Tablet, orodispersible 1,779,247 L.L
N06DA02 DONEPEZIL/ GENEPHARM G Donepezil - 5mg 5mg Tablet, orodispersible 1,634,112 L.L
N06DA02 DONECEPT 10 G Donepezil HCl - 10mg 10mg Tablet, film coated 2,292,595 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 10mg 10mg Tablet, film coated 1,365,344 L.L
N06DA02 DONEPEZIL BIOGARAN G Donepezil HCl - 10mg 10mg Tablet, coated 1,325,029 L.L
N06DA02 DOPEZIL G Donepezil HCl - 10mg 10mg Tablet, film coated 1,381,470 L.L
N06DA02 DONECEPT 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 5mg 5mg Tablet, film coated 1,365,344 L.L
N06DA02 DONEPEZIL BIOGARAN G Donepezil HCl - 5mg 5mg Tablet, coated 1,325,029 L.L
N06DA02 DOPEZIL G Donepezil HCl - 5mg 5mg Tablet, film coated 1,034,759 L.L
C01CA04 DOPAMINE FRESENIUS G Dopamine HCl - 200mg/5ml 200mg/5ml Injectable concentrated solution 713,580 L.L
C01CA04 DOPAMINE RENAUDIN G Dopamine HCl - 200mg/5ml 4% Injectable concentrated solution 1,107,326 L.L
S01EC03 DORZOLAMIDE BGR G Dorzolamide HCl - 20mg/ml 20mg/ml Drops solution 517,379 L.L
N06AA12 DOXEPIN HCl G Doxepin (HCl) - 10mg 10mg Capsule 712,876 L.L
D04AX01 DOXIDERM G Doxepin (HCl) - 5% 5% Cream 1,037,958 L.L
N06AA12 DOXEPIN HCl G Doxepin (HCl) - 50mg 50mg Capsule 965,007 L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 10mg/5ml 10mg/5ml Injectable concentrated solution 428,686 L.L
L01DB01 DOXORUBICINE EBEWE G Doxorubicin HCl - 2mg/ml 50mg/25ml Injectable concentrated solution 1,804,780 L.L
L01DB01 DOXO-CELL G Doxorubicin HCl - 50mg/25ml 50mg/25ml Injectable solution 1,794,030 L.L
L01DB01 DOXORUBICINA PHARMINICIO G Doxorubicin HCl - 50mg/25ml 50mg/25ml Injectable concentrate for solution 2,015,764 L.L
J01AA02 DOXY 100 G Doxycycline (hyclate) - 100mg 100mg Tablet, coated 788,836 L.L
J01AA02 DOXYLAG G Doxycycline (hyclate) - 100mg 100mg Capsule 174,700 L.L
J01AA02 DOXY 50 G Doxycycline (hyclate) - 50mg 50mg Tablet, coated 311,771 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025